1:40 PM
 | 
Nov 01, 2018
 |  BioCentury  |  Finance

OrbiMed’s NASH Terns

Why OrbiMed led $80 million B round for U.S.-China NASH company Terns

Terns Pharmaceuticals Inc. brings a dual U.S.-China strategy and a diverse pipeline to OrbiMed’s non-alcoholic steatohepatitis investment portfolio.

OrbiMed co-led the biotech’s $80 million series B on Oct. 30 with fellow new investor Vivo Capital. Decheng Capital, also a new investor, and existing investor Lilly Asia Ventures also participated.

“We were attracted by the cross-border organization of Terns,” said OrbiMed’s Carl Gordon.

Terns President and CEO Weidong Zhong said the company has a discovery unit in the San Francisco Bay Area...

Read the full 386 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >